Lung Cancer News and Research

Latest Lung Cancer News and Research

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies.

3 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

Clovis Oncology, Inc. and Roche, announced today that they have entered into an agreement to develop an in vitro PCR based companion diagnostic test.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Five organizations receive IASLC travel awards to attend 14th World Conference on Lung Cancer

Five advocacy organizations from India, Australia and the United States have been granted travel awards by the International Association for the Study of Lung Cancer (IASLC) to send representatives to the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Latest Breast cancer screening guidelines deemed unsafe by 80% women

Nearly 80 percent of women feel the new guidelines against breast cancer are unsafe as they stated that screening for those under 50 is not mandatory. The controversy over screening mammography flared up in late 2009, when a government-funded group of independent experts decided to change its recommendations. Instead of advising annual mammograms in all women age 40 and above, the U.S. Preventive Services Task Force (USPSTF) said women shouldn't routinely get screened until they hit 50, and those between 50 and 74 should only have mammograms every two years. But most of the women also seriously overestimate their risk of developing the disease, researchers from the University of Massachusetts Medical School in Worcester found.

31 May 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

Longer looks: Stem cells, vaccinating against addictive drugs, the GOP's budget hatchet man

Krista and Tatiana are not like most other sets of twins. They are connected at their heads, where their skulls merge under a mass of shaggy brown bangs. The girls run and play and go down their backyard slide, but whatever they do, they do together, their heads forever inclined toward each other's, their neck muscles strong and sinuous from a never-ending workout. Twins joined at the head — the medical term is craniopagus — are extremely rare.

27 May 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.

26 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

Olympus ScopeGuide for colonoscopy receives U.S. approval

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products among other core businesses, announces that its revolutionary ScopeGuide- technology can now be used within the United States.

From Evident Corporation - Life Sciences 25 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

A technology that could allow cancer specialists to better determine the most effective chemotherapy treatment for a given patient won the $10,000 in first prize money in the 11th annual Big Bang! Business Plan Competition at the University of California, Davis. The contest is run by MBA students in the Graduate School of Management.

20 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

Lung Cancer News and Research

Latest Lung Cancer News and Research

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Five organizations receive IASLC travel awards to attend 14th World Conference on Lung Cancer

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Latest Breast cancer screening guidelines deemed unsafe by 80% women

YM announces updates on nimotuzumab clinical development program

Longer looks: Stem cells, vaccinating against addictive drugs, the GOP's budget hatchet man

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Olympus ScopeGuide for colonoscopy receives U.S. approval

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in